Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from Mycobacterium tuberculosis

References

• Pasipanodya JG, Gumbo T. A new evolutionary and pharmacokinetic–pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol. 2011;11(5):457–463. doi:10.1016/j.coph.2011.07.00121807559
   PubMed Web of Science ®Google Scholar
• World Health Organization(WHO). Global tuberculosis report 2019. WHO/CDS/TB/2019.20. Geneva, Switzerland: World Health Organization; 2019.
   Google Scholar
• Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405(6789):962–966. doi:10.1038/3501610310879539
   PubMed Web of Science ®Google Scholar
• Wen S, Jing W, Zhang T, et al. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis. 2019;38(7):1293–1296. doi:10.1007/s10096-019-03551-w30953211
   PubMed Web of Science ®Google Scholar
• Keam SJ. Pretomanid: first approval. Drugs. 2019.
   Google Scholar
• Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol. 2009;2(3):215–218. doi:10.4161/cib.2.3.792619641733
   PubMedGoogle Scholar
• Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008;322(5906):1392–1395. doi:10.1126/science.116457119039139
   PubMed Web of Science ®Google Scholar
• Choi KP, Kendrick N, Daniels L. Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis. J Bacteriol. 2002;184(9):2420–2428. doi:10.1128/JB.184.9.2420-2428.200211948155
   PubMed Web of Science ®Google Scholar
• Choi KP, Bair TB, Bae YM, Daniels L. Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by Mycobacterium bovis BCG. J Bacteriol. 2001;183(24):7058–7066. doi:10.1128/JB.183.24.7058-7066.200111717263
   PubMed Web of Science ®Google Scholar
• Manjunatha UH, Lahiri R, Randhawa B, Dowd CS, Krahenbuhl JL, Barry CR. Mycobacterium leprae is naturally resistant to PA-824. Antimicrob Agents Chemother. 2006;50(10):3350–3354. doi:10.1128/AAC.00488-0617005816
   PubMed Web of Science ®Google Scholar
• Haver HL, Adeline C, Pramila G, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59(9):5316–5323. doi:10.1128/AAC.00308-1526100695
   PubMed Web of Science ®Google Scholar
• Cellitti SE, Shaffer J, Jones DH, et al. Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824. Structure. 2012;20(1):101–112. doi:10.1016/j.str.2011.11.00122244759
   PubMed Web of Science ®Google Scholar
• Pang Y, Tan Y, Chen J, et al. Diversity of nontuberculous mycobacteria in eastern and southern China: a cross-sectional study. Eur Respir J. 2017;49:3.
   Web of Science ®Google Scholar
• Naraoka MOMOI, Fukasawa GOTO. Isolation and identification of a naturally occurring 7,8-didemethyl-8-hydroxy-5-deazariboflavin derivative from Mycobacterium avium. BBA - Gen Subj. 1984;797(3):377–380. doi:10.1016/0304-4165(84)90260-5
   Web of Science ®Google Scholar
• Purwantini E, Daniels L. Purification of a novel coenzyme F420-dependent glucose-6-phosphate dehydrogenase from Mycobacterium smegmatis. J Bacteriol. 1996;178(10):2861–2866. doi:10.1128/JB.178.10.2861-2866.19968631674
   PubMed Web of Science ®Google Scholar
• Purwantini E, Gillis TP, Daniels L. Presence of F420-dependent glucose-6-phosphate dehydrogenase in Mycobacterium and Nocardia species, but absence from Streptomyces and Corynebacterium species and methanogenic Archaea. FEMS Microbiol Lett. 1997;146(1):129–134. doi:10.1111/j.1574-6968.1997.tb10182.x8997717
   PubMed Web of Science ®Google Scholar
• Zhang Z, Pang Y, Wang Y, Cohen C, Zhao Y, Liu C. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China. Int J Antimicrob Ag. 2015;45(5):491–495. doi:10.1016/j.ijantimicag.2015.01.012
   Web of Science ®Google Scholar
• Zhang Z, Pang Y, Wang Y, Liu C, Zhao Y. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China. Int J Antimicrob Ag. 2014;43(3):231–235. doi:10.1016/j.ijantimicag.2013.12.007
   Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard, 2nd Ed; CLSI Document M24–A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
   Google Scholar
• Xiao J, Jia H, Pan L, et al. Application of the CRISPRi system to repress sepF expression in Mycobacterium smegmatis. Infect Genet Evol. 2019;72:183–190. doi:10.1016/j.meegid.2018.06.03331242975
   PubMed Web of Science ®Google Scholar
• Wang J, Li BX, Ge PP, et al. Mycobacterium tuberculosis suppresses innate immunity by coopting the host ubiquitin system. Nat Immunol. 2015;16(3):237–245. doi:10.1038/ni.309625642820
   PubMed Web of Science ®Google Scholar
• Rengarajan J, Murphy E, Park A, et al. Mycobacterium tuberculosis Rv2224c modulates innate immune responses. Proc Natl Acad Sci U S A. 2008;105(1):264–269. doi:10.1073/pnas.071060110518172199
   PubMed Web of Science ®Google Scholar
• Lenaerts AJ, Veronica G, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother. 2005;49(6):2294–2301. doi:10.1128/AAC.49.6.2294-2301.200515917524
   PubMed Web of Science ®Google Scholar
• Soni I, De Groote MA, Dasgupta A, Chopra S. Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria. J Med Microbiol. 2016;65(1):1–8. doi:10.1099/jmm.0.00019826515915
   PubMed Web of Science ®Google Scholar
• Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother. 2009;53(9):3720–3725. doi:10.1128/AAC.00106-0919528280
   PubMed Web of Science ®Google Scholar
• Wee WY, Dutta A, Choo SW. Comparative genome analyses of mycobacteria give better insights into their evolution. PLoS One. 2017;12(3):e0172831. doi:10.1371/journal.pone.017283128291784
   PubMed Web of Science ®Google Scholar